The QUILT-88 study reveals promising survival rates for advanced pancreatic cancer patients using a multimodal treatment ...

Heat-triggered release mechanism unequivocally confirmedFavorable safety profile with good tolerability Signs of encouraging ...

In an interview with Targeted OncologyTM, Ravi Muvner, MD, urologist at Hackensack University Medical Center, discusses how targeted therapies have changed the landscape of prostate cancer treatment.

Additionally, multivariable analyses demonstrated that detectable ctDNA before radical cystectomy was associated with a higher risk of nodal disease (OR 5.4, 95% CI 1.9-18.2; p = 0.003) and locally ...

In the neoadjuvant and adjuvant phases of arm C, pembrolizumab will be administered on day 1 and enfortumab vedotin will be administered on days 1 and 8 of each cycle. Enrollment is complete for arm A ...

A new study published in the British Journal of Urology International found that sarcopenia was linked to increased the risk ...

Neoadjuvant chemotherapy and radical cystectomy is the standard treatment for muscle invasive bladder cancer. For patients who are intolerant or unwilling to receive radical surgery and chemotherapy, ...

In June 2025, Merck Sharp & Dohme LLC announced a study are to learn if people who receive intismeran autogene and pembrolizumab are alive and cancer free longer than those who receive placebo and ...

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that eight abstracts featuring data derived from testing with its Decipher Prostate and Decipher Bladder ...

Background: The goal of neoadjuvant therapy for bladder cancer is to improve pathological outcomes and provide patients with the opportunity to preserve the bladder. Disitamab Vedotin, a HER2-targeted ...

With biomarker guidance after neoadjuvant chemotherapy, three-fourths of patients with muscle-invasive bladder cancer (MIBC) avoided cystectomy during 2 years of active surveillance, and almost ...

For the secondary endpoint of overall survival (OS), the durvalumab regimen reduced the risk of death by 25% vs neoadjuvant gemcitabine and cisplatin (OS HR, 0.75 [95% CI, 0.59-0.93]; P =.0106).